Cost-effectiveness analysis in the treatment of hypertension: A medical view

Judith Whitworth, Danielle Lang, David Henry

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)

Abstract

The clinical benefits of anti-hypertensive treatment include reductions in stroke and myocardial infarction, heart failure, renal and ocular damage and possibly cognitive impairment. The cost-effectiveness of treatment generally falls within a range considered acceptable to funders of health care in developed countries, and has been shown to vary with age, gender and pre-treatment blood pressure. In a largely asymptomatic condition, small quality of life impairments resulting from treatment could offset these clinical and economic benefits, but evidence suggests that treatment is associated with slight improvements in quality of life. A limitation of these analyses is that the needs of developing countries are not met. The cost- effectiveness of anti-hypertensive treatment may be unattractive to developing countries when compared with interventions that achieve greater health gains per dollar spent.

Original languageEnglish
Pages (from-to)999-1008
Number of pages10
JournalClinical and Experimental Hypertension
Volume21
Issue number5-6
DOIs
Publication statusPublished - 1999
Externally publishedYes

Fingerprint

Antihypertensive Agents
Developing Countries
Cost-Benefit Analysis
Quality of Life
Hypertension
Asymptomatic Diseases
Developed Countries
Heart Failure
Stroke
Myocardial Infarction
Economics
Blood Pressure
Delivery of Health Care
Kidney
Health
Cognitive Dysfunction

Cite this

@article{f7ebe7585300433d9df4c1aa53cb5ebc,
title = "Cost-effectiveness analysis in the treatment of hypertension: A medical view",
abstract = "The clinical benefits of anti-hypertensive treatment include reductions in stroke and myocardial infarction, heart failure, renal and ocular damage and possibly cognitive impairment. The cost-effectiveness of treatment generally falls within a range considered acceptable to funders of health care in developed countries, and has been shown to vary with age, gender and pre-treatment blood pressure. In a largely asymptomatic condition, small quality of life impairments resulting from treatment could offset these clinical and economic benefits, but evidence suggests that treatment is associated with slight improvements in quality of life. A limitation of these analyses is that the needs of developing countries are not met. The cost- effectiveness of anti-hypertensive treatment may be unattractive to developing countries when compared with interventions that achieve greater health gains per dollar spent.",
author = "Judith Whitworth and Danielle Lang and David Henry",
year = "1999",
doi = "10.3109/10641969909061027",
language = "English",
volume = "21",
pages = "999--1008",
journal = "Clinical and Experimental Hypertension",
issn = "1064-1963",
publisher = "Informa Healthcare USA",
number = "5-6",

}

Cost-effectiveness analysis in the treatment of hypertension : A medical view. / Whitworth, Judith; Lang, Danielle; Henry, David.

In: Clinical and Experimental Hypertension, Vol. 21, No. 5-6, 1999, p. 999-1008.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Cost-effectiveness analysis in the treatment of hypertension

T2 - A medical view

AU - Whitworth, Judith

AU - Lang, Danielle

AU - Henry, David

PY - 1999

Y1 - 1999

N2 - The clinical benefits of anti-hypertensive treatment include reductions in stroke and myocardial infarction, heart failure, renal and ocular damage and possibly cognitive impairment. The cost-effectiveness of treatment generally falls within a range considered acceptable to funders of health care in developed countries, and has been shown to vary with age, gender and pre-treatment blood pressure. In a largely asymptomatic condition, small quality of life impairments resulting from treatment could offset these clinical and economic benefits, but evidence suggests that treatment is associated with slight improvements in quality of life. A limitation of these analyses is that the needs of developing countries are not met. The cost- effectiveness of anti-hypertensive treatment may be unattractive to developing countries when compared with interventions that achieve greater health gains per dollar spent.

AB - The clinical benefits of anti-hypertensive treatment include reductions in stroke and myocardial infarction, heart failure, renal and ocular damage and possibly cognitive impairment. The cost-effectiveness of treatment generally falls within a range considered acceptable to funders of health care in developed countries, and has been shown to vary with age, gender and pre-treatment blood pressure. In a largely asymptomatic condition, small quality of life impairments resulting from treatment could offset these clinical and economic benefits, but evidence suggests that treatment is associated with slight improvements in quality of life. A limitation of these analyses is that the needs of developing countries are not met. The cost- effectiveness of anti-hypertensive treatment may be unattractive to developing countries when compared with interventions that achieve greater health gains per dollar spent.

UR - http://www.scopus.com/inward/record.url?scp=0032792743&partnerID=8YFLogxK

U2 - 10.3109/10641969909061027

DO - 10.3109/10641969909061027

M3 - Article

VL - 21

SP - 999

EP - 1008

JO - Clinical and Experimental Hypertension

JF - Clinical and Experimental Hypertension

SN - 1064-1963

IS - 5-6

ER -